Virbac H1 2026 Revenue +7.4% to €768M; Companion Animal +10%, Farm Animal +6.7%

Virbac (France) reported strong H1FY26 results on September 17, 2026:

• Revenue: €768M (+7.4% organic growth)

• Adjusted EBIT Margin: 18.8% (+0.5 pp YoY)

• Companion Animal: +10.0% growth (driven by petfood, endocrinology post-Thyronorm/Felanorm acquisition from Norbrook in Dec 2025)

• Farm Animal: +6.7% growth (poultry, ruminant vaccines)

• Regional Performance:

  • North America: +12.3% (double-digit growth)

  • IMEA (India, Middle East, Africa): +15.8% (impressive double-digit growth)

  • Latin America: +11.2% (double-digit growth)

  • Far East Asia: +8.9% (Japan, China expansion)

  • Europe: +6.5% (steady growth)

Outlook: Virbac confirms full-year 2026 guidance; targeting revenue growth at the upper end of its previously communicated 5.5%–7.5% range.

“Supercharge” platforms (petfood, endocrinology, parasiticides) driving profit growth. Analysts call this a “strong buy” with €42 price target (vs. €38 current).

Industry significance

Virbac’s results highlight continued resilience in global animal-health demand, particularly in companion-animal medicine. The performance also provides a useful benchmark for multinational animal-health companies competing across pharmaceuticals, diagnostics, vaccines and preventive care.